BTAI - BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12 2024 | Benzinga
NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2023 financial results on Tues., March 12, 2024, before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company's financial results and provide a general business update.
| Conference Call & Webcast Details |
| Date/Time: |
| Tues., March 12, 2024, at 8:00 AM ET |
| Domestic: |
| 877-407-5795 |
| International: |
| 201-689-8722 |
The webcast link will be accessible under "News/Events" on the Investors & Media page of the Company's website at www.bioxceltherapeutics.com.
| Replay* |
| Domestic: |
| 877-660-6853 |
| International: |
| 201-612-7415 |
| Conference ID: |
| 13744874 |
*Replay available through June 12, 2024
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (NASDAQ: